Corcept Therapeutics (CORT) Competitors $69.68 +1.53 (+2.24%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector. Corcept Therapeutics vs. Its Competitors Annovis Bio Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Is CORT or ANVS more profitable? Corcept Therapeutics has a net margin of 19.33% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.40% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics19.33% 20.40% 16.64% Annovis Bio N/A -300.56%-193.50% Which has better valuation and earnings, CORT or ANVS? Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$685.45M10.78$141.21M$1.1660.07Annovis BioN/AN/A-$24.59M-$2.16-1.26 Does the media favor CORT or ANVS? In the previous week, Corcept Therapeutics had 20 more articles in the media than Annovis Bio. MarketBeat recorded 21 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.90 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CORT or ANVS? Corcept Therapeutics presently has a consensus target price of $138.25, suggesting a potential upside of 98.39%. Annovis Bio has a consensus target price of $18.00, suggesting a potential upside of 562.98%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CORT or ANVS? 93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 20.8% of Corcept Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, CORT or ANVS? Corcept Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. SummaryCorcept Therapeutics beats Annovis Bio on 11 of the 15 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.40B$2.70B$5.53B$8.98BDividend YieldN/A1.79%5.25%4.04%P/E Ratio60.129.1627.0720.16Price / Sales10.78756.20430.62124.91Price / Cash54.38159.8036.8257.86Price / Book10.744.608.075.57Net Income$141.21M$31.26M$3.17B$248.52M7 Day Performance-2.32%6.61%3.91%5.05%1 Month Performance-1.25%3.75%3.63%6.98%1 Year Performance133.06%3.11%34.00%21.36% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.6905 of 5 stars$69.69+2.2%$138.25+98.4%+131.0%$7.40B$685.45M60.12300ANVSAnnovis Bio1.6462 of 5 stars$2.18+6.3%$30.25+1,287.6%-83.6%$42.49MN/A-1.013RPRXRoyalty Pharma4.8861 of 5 stars$36.03+0.4%$47.33+31.4%+38.1%$20.26B$2.26B19.4880Positive NewsJAZZJazz Pharmaceuticals4.8937 of 5 stars$106.12-0.7%$184.00+73.4%+8.4%$6.42B$4.07B14.152,800PRGOPerrigo4.8429 of 5 stars$26.73+0.7%$33.00+23.5%+5.6%$3.67B$4.37B-20.408,379SUPNSupernus Pharmaceuticals2.8416 of 5 stars$31.52+1.2%$36.00+14.2%+22.3%$1.76B$661.82M28.40580PCRXPacira BioSciences3.4329 of 5 stars$23.90+1.8%$26.44+10.6%+12.5%$1.11B$702.77M-10.48720NKTRNektar Therapeutics4.8111 of 5 stars$25.84+0.3%$84.17+225.7%+22.2%$320.67M$98.43M-2.69220Analyst ForecastGap UpHigh Trading VolumeOMEROmeros3.2764 of 5 stars$3.00-6.3%$18.00+500.0%-19.5%$175.77MN/A-1.13210ASMBAssembly Biosciences3.7657 of 5 stars$18.12+4.7%$33.00+82.1%+30.6%$138.44M$28.52M-2.91100Trending NewsHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5937 of 5 stars$3.35+28.8%N/A+107.4%$50.12M$37.87M-13.4080News Coverage Related Companies and Tools Related Companies Annovis Bio Competitors Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CORT Stock Alerts